GRAHAM STEPHEN X

Director sold 20,000 shares (20.0K) for $9.0M at blended $451.36; stock now 14.8% below peak

GRAHAM STEPHEN X, a Director, completed 4 separate sales totaling 20,000 shares for $9,027,275.62 on 2024-11-21, executed across a narrow price band ($449.66–$453.16) suggesting a staged liquidation. This sale reduced his holdings by 74.2% from 26,970 shares to 6,970 shares. Notably, his cross-ticker track record shows an average 90-day return of -79.8% after sells with a 100.00% well-timed rate, though at MSTR specifically, only 1 prior measurable sale (on 2024-02-28) posted a -82.4% 90-day return. The stock has since declined 14.8% from its 52-week high of $473.83 to the current $403.45, roughly 10.6% below the transaction prices, but remains up 72.2% over 30 days and up 188.2% over 90 days—placing this sale near, but not at, the peaks in the recent rally. The company's fundamentals show a net loss of $340.2M on $116.1M quarterly revenue with near-flat annual growth (-0.6%), creating a context where opportunistic liquidation at near-peak prices may be consistent with prior pattern rather than new concern.

MSTR director Graham sells 30,000 shares (81.1% of holdings) for $11.4M; prior MSTR sales showed -77% to -82% 90-day returns

Director Stephen X Graham sold 30,000 shares across four separate transactions on 2024-11-13 for a blended average price of $380.73, reducing his holdings from 36,970 to 6,970 shares (an 81.1% reduction). The timing merits attention: Graham's four prior sales at MSTR all achieved negative 90-day returns ranging from -77.1% to -82.4%, with a 100% well-timed rate at the 90-day mark. His cross-ticker track record shows similar consistency with an average 90-day return of -79.8% across all prior sells. Against this historical pattern of selling into price peaks, the stock has since declined 8.1% from its 52-week high of $356.59, though the current price of $327.67 still remains above the transaction price. The company reports negative net income of $-340.2M in the latest quarter with negligible annual revenue growth of -0.6%, raising questions about fundamental support for the elevated valuations at which this insider has historically offloaded shares.